Sanofi Commits $180M for Kali's Novel Trispecific Antibody in Autoimmune Disease Partnership
核心洞察
Sanofi has secured exclusive worldwide rights to KT501 (搜索), a first-in-class trispecific T-cell engager targeting CD3 (搜索), CD19 (搜索), and BCMA (搜索) for autoimmune diseases (搜索), with $180 million in near-term payments.
The deal includes up to $1.05 billion in development and commercial milestones plus tiered royalties, representing Kali Therapeutics (搜索)' first major pharma partnership.
KT501 (搜索) recently entered Phase 1a clinical trials for rheumatoid arthritis (搜索), utilizing Kali's proprietary CD3 (搜索)-masking platform designed to minimize cytokine release syndrome (搜索) while maximizing B-cell depletion.
California biotech Kali Therapeutics (搜索) has secured its first major pharmaceutical partnership with Sanofi, which committed $180 million in near-term payments for exclusive worldwide rights to KT501 (搜索), a novel trispecific T-cell engager designed for autoimmune diseases (搜索). The comprehensive agreement includes up to $1.05 billion in development and commercial milestone payments, along with tiered royalties ranging from high single digits to double digits if the therapy reaches market.
Novel Trispecific Design Targets Multiple B-Cell Populations
KT501 (搜索) represents a first-in-class CD19xBCMAxCD3 trispecific antibody that simultaneously binds to three antigens found on B-cell surfaces. Unlike traditional B-cell therapies, KT501 is engineered to target a broad spectrum of B-cell populations, including plasma cells, by simultaneously binding to CD19 (搜索) and BCMA (搜索). This multi-targeted approach addresses limitations of previous-generation therapies that often spare the cells responsible for autoantibody production.
The trispecific has been developed using Kali's proprietary drug discovery platform, which generates T-cell engagers with precise immune system targeting combined with masking technology designed to avoid off-target side effects. Studies in non-human primates demonstrated strong B-cell depletion capabilities while limiting common side effects of T-cell engagers, including minimizing cytokine release that can cause potentially serious adverse reactions.
Clinical Development Underway
Earlier this month, Kali initiated dosing in a first-in-human Phase 1a trial targeting enrollment of 24 adult subjects with rheumatoid arthritis (搜索). The open-label, dose-escalation study evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics of KT501 (搜索) administered as a single subcutaneous injection. Patients receive ascending doses of the T-cell engager, with results expected in 2027.
"Entering the clinic with KT501 (搜索) is a defining moment for Kali Therapeutics (搜索). It marks our transition from a discovery-focused organization to a clinical-stage company dedicated to delivering functional cures for patients with autoimmune diseases (搜索)," said Weihao Xu, CEO of Kali Therapeutics. "By advancing our lead candidate into human trials, we are now positioned to evaluate our 'Immune Reset' hypothesis in a clinical setting."
The Phase 1a study will rigorously characterize B-cell kinetics, cytokine release profiles, and other relevant pharmacodynamic markers to demonstrate KT501 (搜索)'s potential to induce a deep "immune reset" safely. The subcutaneous delivery method and "off-the-shelf" availability provide scalable and convenient alternatives to complex cell-based therapies.
Strategic Significance for Sanofi's Pipeline
For Sanofi, the KT501 (搜索) partnership continues a series of licensing agreements in immunology and inflammation as the company prepares for potential loss of market exclusivity for Dupixent (dupilumab) in the early 2030s. The Regeneron-partnered IL-4 (搜索) and IL-13 (搜索) inhibitor generates over $18 billion in annual revenue as Sanofi's blockbuster therapy.
This month, Sanofi also committed $135 million upfront for rights to Hong Kong-based Sino Biopharmaceutical's JAK (搜索)/ROCK (搜索) inhibitor rovadicitinib in a deal worth up to $1.53 billion. In January, the company expanded an alliance with US biotech Earendil Labs (搜索) covering multiple AI-derived drug candidates, including inflammatory bowel disease (搜索) candidates. Last year, Sanofi strengthened its long-term immunology pipeline through deals with Dren Bio (搜索) and EVOQ Therapeutics (搜索).
Technology Platform Addresses Safety Concerns
Kali's platform leverages protein engineering to address complex therapeutic challenges associated with T-cell engagers. The proprietary CD3 (搜索)-masking technology aims to decouple potency from toxicity, potentially providing safer and more effective treatment options for patients with autoimmune diseases (搜索).
"This collaboration highlights the potential of our unique CD3 (搜索) masking technology to decouple potency from toxicity, aiming to provide safer, more effective options for patients," commented Xu. The masking approach is designed to maximize B-cell killing potency while significantly reducing the risk of cytokine release syndrome (搜索), a common hurdle for T-cell engaging therapies.
Min Bao, M.D., Chief Medical Officer of Kali Therapeutics (搜索), emphasized the therapy's potential for achieving "fundamental 'immune reset' across a broad range of B-cell driven autoimmune diseases (搜索)." The subcutaneous injection method offers significant advantages in ease of use and dosing flexibility compared to existing treatment approaches.